J
Jiangsu Shengsi Biopharmaceutical
Suns Bio Group is a biopharmaceutical company
About Jiangsu Shengsi Biopharmaceutical
Gensciences Inc. is advancing the treatment of hemophilia through its development of ultra long-acting recombinant coagulation factor VIII, currently in Phase III clinical trials. The company aims to demonstrate the hemostatic potency of its product, SS315, both in vitro and in vivo, while also evaluating the safety, immunogenicity, and pharmacokinetic/pharmacodynamic characteristics of SS109 in patients with hemophilia who have inhibitors. Gensciences targets a niche market of hemophilia patients requiring bypassing agents, offering a solution with a longer half-life and improved hemostasis compared to existing treatments. The business model likely involves clinical trials, regulatory approvals, and partnerships with healthcare providers to bring its product to market. Revenue generation would stem from the commercialization of its therapeutic solutions for hemophilia management.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES D✓Equity / VC | Jun 2024 | $28M | $825M | Tencent · Zhangjiang Hi-Tech Park | ↗ |
| SERIES AEquity / VC | Mar 2021 | — | — | IDG Capital · Hygeia Capital | — |
Growth signals
Latest recorded traffic for Jiangsu Shengsi Biopharmaceutical is 1.2K monthly website visits, up 150% over the last three months. Jiangsu Shengsi Biopharmaceutical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Jiangsu Shengsi Biopharmaceutical in its local ecosystem
The Jiangsu Shengsi Biopharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
IDG Capital
Hygeia Capital
Series B and later2 investors entered at this stage
Tencent- ZPZhangjiang Hi-Tech Park
Other known investors1 additional known investor
University of Chinese Academy of Sciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jiangsu Shengsi Biopharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jiangsu Shengsi Biopharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










